165 related articles for article (PubMed ID: 32600694)
1. A potential strategy for in-stent restenosis: Inhibition of migration and proliferation of vascular smooth muscle cells by Cu ion.
Zhang Y; Wang X; Ma Z; Bai B; Liu J; Yang L; Qin G; Zhang E
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111090. PubMed ID: 32600694
[TBL] [Abstract][Full Text] [Related]
2. Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells.
Lu L; Wang YN; Sun WH; Liu ZH; Zhang Q; Pu LJ; Yang K; Wang LJ; Zhu ZB; Meng H; Yang P; Du R; Chen QJ; Wang LS; Yu H; Shen WF
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):572-80. PubMed ID: 23372061
[TBL] [Abstract][Full Text] [Related]
3. The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro.
Kastl SP; Katsaros KM; Krychtiuk KA; Jägersberger G; Kaun C; Huber K; Wojta J; Speidl WS
PLoS One; 2020; 15(5):e0232483. PubMed ID: 32392256
[TBL] [Abstract][Full Text] [Related]
4. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
[TBL] [Abstract][Full Text] [Related]
5. Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis.
Hytönen J; Leppänen O; Braesen JH; Schunck WH; Mueller D; Jung F; Mrowietz C; Jastroch M; von Bergwelt-Baildon M; Kappert K; Heuser A; Drenckhahn JD; Pieske B; Thierfelder L; Ylä-Herttuala S; Blaschke F
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1534-48. PubMed ID: 27283742
[TBL] [Abstract][Full Text] [Related]
6. Effects of elemene on inhibiting proliferation of vascular smooth muscle cells and promoting reendothelialization at the stent implantation site.
Sun W; Huang Y; Yin T; Wang J; Du R; Qiu J; Zhang Y; Wang Y; Chen J; Wang G
Biomater Sci; 2017 May; 5(6):1144-1155. PubMed ID: 28503689
[TBL] [Abstract][Full Text] [Related]
7. Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis.
Zamani M; Prabhakaran MP; Varshosaz J; Mhaisalkar PS; Ramakrishna S
Acta Biomater; 2016 Sep; 42():316-328. PubMed ID: 27397493
[TBL] [Abstract][Full Text] [Related]
8. Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Effectively Prevents Experimental In-Stent Restenosis.
Wang D; Deuse T; Stubbendorff M; Chernogubova E; Erben RG; Eken SM; Jin H; Li Y; Busch A; Heeger CH; Behnisch B; Reichenspurner H; Robbins RC; Spin JM; Tsao PS; Schrepfer S; Maegdefessel L
Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):1945-53. PubMed ID: 26183619
[TBL] [Abstract][Full Text] [Related]
9. Increment of HFABP Level in Coronary Artery In-Stent Restenosis Segments in Diabetic and Nondiabetic Minipigs: HFABP Overexpression Promotes Multiple Pathway-Related Inflammation, Growth and Migration in Human Vascular Smooth Muscle Cells.
Chen K; Chen QJ; Wang LJ; Liu ZH; Zhang Q; Yang K; Wang HB; Yan XX; Zhu ZB; Du R; Zhang RY; Shen WF; Lu L
J Vasc Res; 2016; 53(1-2):27-38. PubMed ID: 27372431
[TBL] [Abstract][Full Text] [Related]
10. A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan.
Segev A; Nili N; Osherov AB; Qiang B; Wong AJ; Pillarisetti S; Strauss BH
EuroIntervention; 2010 May; 6(1):134-40. PubMed ID: 20542809
[TBL] [Abstract][Full Text] [Related]
11. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
[TBL] [Abstract][Full Text] [Related]
12. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach.
Ng XW; Huang Y; Liu KL; Lim SG; Chen HH; Burnett JC; Freddy Boey YC; Venkatraman SS
J Pharm Sci; 2014 Nov; 103(11):3631-3640. PubMed ID: 25223419
[TBL] [Abstract][Full Text] [Related]
14. Secreted Matrix Metalloproteinase-9 of Proliferating Smooth Muscle Cells as a Trigger for Drug Release from Stent Surface Polymers in Coronary Arteries.
Gliesche DG; Hussner J; Witzigmann D; Porta F; Glatter T; Schmidt A; Huwyler J; Meyer Zu Schwabedissen HE
Mol Pharm; 2016 Jul; 13(7):2290-300. PubMed ID: 27241028
[TBL] [Abstract][Full Text] [Related]
15. Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis.
Kong J; Hou J; Ma L; Xing L; Jia H; Liu H; Zhang S; Yu B; Jang IK
Arch Cardiovasc Dis; 2013 Feb; 106(2):79-85. PubMed ID: 23527911
[TBL] [Abstract][Full Text] [Related]
16. Drug-eluting stent specifically designed to target vascular smooth muscle cell phenotypic modulation attenuated restenosis through the YAP pathway.
Huang C; Zhang W; Zhu Y
Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H541-H551. PubMed ID: 31298560
[TBL] [Abstract][Full Text] [Related]
17. Increased serum TREM-1 level is associated with in-stent restenosis, and activation of TREM-1 promotes inflammation, proliferation and migration in vascular smooth muscle cells.
Wang F; Li C; Ding FH; Shen Y; Gao J; Liu ZH; Chen JW; Zhang RY; Shen WF; Wang XQ; Lu L
Atherosclerosis; 2017 Dec; 267():10-18. PubMed ID: 29080545
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.
Curcio A; Torella D; Indolfi C
Circ J; 2011; 75(6):1287-96. PubMed ID: 21532177
[TBL] [Abstract][Full Text] [Related]
19. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53.
Rosner D; McCarthy N; Bennett M
Cardiovasc Res; 2005 Jun; 66(3):601-10. PubMed ID: 15914125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
